Stock Market Wire News Logo
Stock Market Wire News Logo
    • Login
    • Sign Up
MoMoGains MoMoGains
NEXT ALERT COUNTDOWN
Stock Information

MannKind Corporation Company Name:

MNKD Stock Symbol:

NASDAQ Market:

MannKind Corporation Website:

MannKind Expands Commercial Scale Manufacturing Capabilities for High-Potency Molecules

MENU
MNKD MNKD Quote MNKD Short MNKD News MNKD Articles MNKD Message Board
Get MNKD Alerts

News, Short Squeeze, Breakout and More Instantly...

RECENT MNKD NEWS
  • MNKD - MannKind: December MidCap Requirement And Afrezza Losses

    As December comes to an end, two events will influence MannKind ( MNKD ) share price in the near term: (1) the MidCap December $27 million trailing 12-month net revenue, and (2) the expiration of 23.3 million warrants exercisable at a price of $1.60. These two events are offsetting keeping sha...

  • MNKD - MannKind: New Loan Structure Leads To Financial Uncertainty

    MannKind ( MNKD ) is a biotech that is dependent on selling of common shares and borrowing from lenders to sustain operations. Without a guaranteed lending source, MannKind's operations could come to a halt. Wall Street doesn't like uncertainty, and by my calculations MannKind has violated a c...

  • MNKD - MannKind Corporation to Present at the Piper Jaffray 31st Annual Healthcare Conference

    WESTLAKE VILLAGE, Calif., Nov. 29, 2019 (GLOBE NEWSWIRE) -- MannKind Corporation (NASDAQ: MNKD) , a company focused on the development and commercialization of inhaled therapeutic products for patients with diseases such as diabetes and pulmonary arterial hypertension, announced today that...

MannKind Expands Commercial Scale Manufacturing Capabilities for High-Potency Molecules


home / news releases / MannKind Expands Commercial Scale Manufacturing Capabilities for High-Potency Molecules

  • July, 11 2019 04:14 PM
  • |
  • GlobeNewswire
  • |
    • MNKD
    • MNKD Quote
    • MNKD Short
    • MNKD News
    • MNKD Articles
    • MNKD Message Board

WESTLAKE VILLAGE, Calif., July 11, 2019 (GLOBE NEWSWIRE) -- MannKind Corporation (Nasdaq:MNKD), a company focused on the development and commercialization of inhaled therapeutic products for patients with diseases such as diabetes and pulmonary arterial hypertension, announced that it has completed construction of a new high-potency manufacturing suite in its Danbury Connecticut facility.  This expansion provides the Company with the capability to produce dry powder formulations of highly potent active ingredients, such as epinephrine, on a commercial scale, in alignment with MannKind's strategic partnerships. The new suite will house bulk powder formulation and fill/pack operations for high-potency powders and adds to MannKind's extensive commercial manufacturing capability, which includes inhalation devices, large-scale compounding, particle formation, tangential flow filtration, cryogranulation, and high capacity (300 kg/day) lyophilization.

“This expansion will allow us to utilize more fully the capacity of our world class, FDA-approved manufacturing facility for dry powder inhalation products.  We are also pursuing opportunities to utilize our lyophilization capacity to fulfill the needs of our industry and drug development partners," stated Joe Kocinsky, Chief Technology Officer of MannKind.

About MannKind Corporation
MannKind Corporation (NASDAQ:MNKD) focuses on the development and commercialization of inhaled therapeutic products for patients with diseases such as diabetes and pulmonary arterial hypertension. MannKind is currently commercializing Afrezza® (insulin human) Inhalation Powder, the Company's first FDA approved product and the only inhaled rapid-acting mealtime insulin in the United States, where it is available by prescription from pharmacies nationwide. MannKind is headquartered in Westlake Village, California, and has a state-of-the art manufacturing facility in Danbury, Connecticut. The Company also employs field sales and medical representatives across the U.S. For further information, visit www.mannkindcorp.com.

MannKind Contact:

Rose Alinaya
Investor Relations
818-661-5000
ir@mannkindcorp.com

Tags
  • Pharmaceutical
  • Healthcare
  • Manufacturing and Engineering
Share This Post

Market Wire News is a media platform, the information on this page was provided by GlobeNewswire via Quote Media. Read our full disclaimer.

Contact the Author

  • Research
  • Stock Search
  • News Releases
  • Articles
  • Message Boards
  • Trending Stocks
  • Short Information
  • Stock Wall
  • Member Benefits
  • Member Coins
  • Sign Up
  • Login
  • Contact

Sign up or login to continue

Sign up or login to continue.




Advertise

Brand your company, advertise your products or services with our ad programs.

Advertise

Research

Stock Search

News Releases

Articles

Message Boards

Trending Stocks

Short Information

Stock Wall

Members

Member Benefits

Member Coins


Log In

Sign Up

Stay Connected
Follow @marketWN

Contact

Privacy

Terms of Service

Disclaimer

© 2018 Market Wire News